2Blum D, Muller T, Kulm W, et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients[J]. Neurosci Lett,1995 ;202:17-20.
4Fcrrari CC, Port Godoy MC, Tarelli R, et al. Progressive neurodegeneration and motor disabilities induced by chronoc expression of IL-beta in the substantia nigra[J]. Neurobiol Dis,2006 ;24( 1 ) :183-93.
5Shen YQ,Hebert G,Su Y,et al. In mice,preduction of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization[J]. Brain Res,2005 ;1045 (1-2) :31-7.
6Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor alpha and elevated in the brain from Parkinson patients[J]. Neurosci Lett,1994;180:147-50.
7Hasegawa Y,Inagaki T,Sawada M ,et al. Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease[J]. Acta Neurol Stand,2000 ; 101 (3) : 159-64.
8Moller JC,Depbedylu C,Kolsch H,et al. Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson' s disease[J]. Neurosci Lett,2004 ;359(3) :195-7.
9McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1 beta polynorphisms with idiopathic Parkinson' s disease[J]. Neurosci Lett, 2002;326( 1 ) :67-9.
10Nishimura M, Kuno S, Kaji R,et al. Glutathione-S-transferase and interleukin-1 beta gene polymorphisms in Japanese patients with Parkinson's disease[J]. Mov Disord,2005 ;20(7) :901-2.
2Vila M, Jackson LV, Vukosavic S et al. Bax ablation prevents dopaminergic neurodegeneration in the l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine mouse model of Paddnson disease[J]. Proe Nail Aead Sci U. S. A., 2001, 98:2837-2842.
3Yang L, Matthews RT, Schulz JB et al. l-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2 [J]. J Neurosci, 1998, 18:8145-8152.
4Hartmann A, Hunot S, Michel PP et al. Caspase 3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson disease[J]. Proc Nail Aead Sci U. S. A., 2000, 97:2875-2880.
5Mogi M, Togahi A, Ogana M et al. Effects of repeated systemic administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) to mice on intedeukin-1βand nerve growth factors[J]. Neurosci Lett, 1998, 250:25-28.
6Mogi M, Harada M, Narabayashi H et al. Interleukin(IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson disease[J]. Neurosci Lett, 1996,211:13-16.
7Hengartner MO. The biochemistry of apoptosis[ J ]. Nature,2000, 407:770-776.
8Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labeling and acridine orange staining[J]. Neuroscienee, 1997, 77:1037-1048.
9Chen JY, Hsu PC, Hsu LL et al. Sequential upregulation if the c-fos and bax genes in the cortex, striatmn and cerebellum induced by a single injection of a low dose of l-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine(MPTP) in C57BL/6 mice[J]. Neurosci Lett, 2001, 314:49-52.
10Nagatsu T, Mogi M, Ichinose H et al. Changes in cytokines and neurotrophins in Parkinson disease[J]. J Neural Transm Suppl, 2000, 60:277-90.
